CRF2R Agonist Treatment Slows Disease Progression in Mdx Mice
Author Information
Author(s): Richard T Hinkle, Frank R Lefever, Elizabeth T Dolan, Deborah L Reichart, Jefferey A Dietrich, Kathryn E Gropp, Robert I Thacker, Jeffrey P Demuth, Paula J Stevens, Xiaoyan A Qu, Alex R Varbanov, Feng Wang, Robert J Isfort
Primary Institution: Procter & Gamble Pharmaceuticals, Mason, OH, USA
Hypothesis
Does corticotrophin releasing factor 2 receptor (CRF2R) agonist treatment prevent the loss of diaphragm function in mdx mice?
Conclusion
CRF2R activation can prevent the progressive degeneration of diaphragm muscle associated with dystrophin gene mutation.
Supporting Evidence
- CRF2R agonist treatment blocked the loss of diaphragm specific force.
- Combination treatment with glucocorticoids and CRF2R agonist increased diaphragm specific force.
- Histopathological analysis showed reduced fibrosis and inflammation in treated mice.
Takeaway
Giving a special medicine to mice with a muscle disease helps their muscles stay strong and healthy for longer.
Methodology
Mdx mice were treated with CRF2R agonist PG-873637 and glucocorticoids, and diaphragm function was analyzed over three months.
Potential Biases
Potential bias due to the involvement of Procter & Gamble employees in the study.
Limitations
The study was conducted on a specific mouse model, which may not fully represent human conditions.
Participant Demographics
Male mdx mice aged 2-3 months were used in the study.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website